| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4005408 | American Journal of Ophthalmology | 2006 | 13 Pages |
Abstract
Intraocular injections of ranibizumab significantly reduced foveal thickness and improved visual acuity in 10 patients with DME, which demonstrated that VEGF is an important therapeutic target for DME. A randomized, controlled, double-masked trial is needed to test whether intraocular injections of ranibizumab provide long-term benefit to patients with DME.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Quan Dong MD, MSc, Sinan MD, Syed Mahmood MBBS, Julia A. MD, Edward MD, Jennifer MD, Ingrid MD, Diana V. MD, Peter A. MD,